Avalyn Pharma (NASDAQ:AVLN) Shares Up 5.3% – What’s Next?

Avalyn Pharma Inc. (NASDAQ:AVLN)’s share price was up 5.3% during trading on Friday . The company traded as high as $27.76 and last traded at $27.04. 63,435 shares were traded during trading, a decline of 84% from the average daily volume of 400,026 shares. The stock had previously closed at $25.68.

Wall Street Analyst Weigh In

Several research firms have issued reports on AVLN. Jefferies Financial Group assumed coverage on Avalyn Pharma in a research note on Monday, May 25th. They issued a “buy” rating and a $52.00 price objective on the stock. Evercore began coverage on Avalyn Pharma in a report on Tuesday, May 26th. They set an “outperform” rating and a $51.00 target price on the stock. Guggenheim started coverage on Avalyn Pharma in a research note on Monday, May 25th. They issued a “buy” rating and a $80.00 price target on the stock. Zacks Research raised Avalyn Pharma to a “hold” rating in a report on Wednesday, May 27th. Finally, Morgan Stanley assumed coverage on shares of Avalyn Pharma in a research report on Tuesday, May 26th. They set an “overweight” rating and a $53.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $59.00.

Avalyn Pharma Trading Up 7.7%

The stock has a market cap of $1.23 billion and a P/E ratio of -1.27. The company has a 50 day moving average of $28.86.

Avalyn Pharma (NASDAQ:AVLN) last issued its quarterly earnings data on Wednesday, June 3rd. The company reported ($21.83) EPS for the quarter, missing analysts’ consensus estimates of ($16.38) by ($5.45).

Insider Transactions at Avalyn Pharma

In other Avalyn Pharma news, Director Jill Carroll acquired 277,778 shares of the company’s stock in a transaction on Friday, May 1st. The stock was acquired at an average price of $18.00 per share, for a total transaction of $5,000,004.00. Following the purchase, the director directly owned 2,186,562 shares of the company’s stock, valued at $39,358,116. This trade represents a 14.55% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of the business’s stock in a transaction on Friday, May 1st. The stock was acquired at an average cost of $18.00 per share, with a total value of $9,999,990.00. Following the acquisition, the insider directly owned 2,186,562 shares in the company, valued at approximately $39,358,116. This trade represents a 34.06% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.